Reduced tumor growth by single treatment when given early. Effective in TLR4-defective mice. No change frequencies of myeloid or lymphoid immune cells in tumor but change towards an M1/antitumor phenotype. Synergistic effect when combined with CPI. This evidence concerns the gene TLR4 and neoplasm.